Evidence map›Paper›PMID 37296954›Full record

ArticleCancers2023

Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study.

Francesca R Mauro, Diana Giannarelli, Clementina M Galluzzo, Andrea Visentin, Anna M Frustaci, Paolo Sportoletti, Candida Vitale, Gianluigi Reda, Massimo Gentile, Luciano Levato and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 14 institutions in 1 country.

Francesca R MauroHematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy.ORCID 0000-0003-2425-9474
Diana GiannarelliDesign and Analysis of Clinical Trials Unit, Scientific Directorate, IRCS Fondazione Policlinico Universitario A. Gemelli, 00168 Rome, Italy.
Clementina M GalluzzoNational Center for Global Health, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0003-1392-6569
Andrea VisentinHematology and Clinical Immunology Unit, Department of Medicine, University of Padua, 35122 Padova, Italy.ORCID 0000-0003-0271-7200
Anna M FrustaciASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.ORCID 0000-0003-2587-7901
Paolo SportolettiInstitute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06129 Perugia, Italy.ORCID 0000-0002-5630-9862
Candida VitaleDepartment of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10125 Torino, Italy.ORCID 0000-0002-2592-8724
Gianluigi RedaHematology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Massimo GentileHematology Unit AO of Cosenza, Cosenza and Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.ORCID 0000-0002-5256-0726
Luciano LevatoDepartment Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy.
Roberta MurruHematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS "G. Brotzu", 09134 Cagliari, Italy.
Daniele ArmientoUnit of Hematology, Stem Cell Transplantation, University Campus Bio-Medico, 00128 Rome, Italy.
Maria C MolinariHematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy.
Giulia ProiettiHematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy.ORCID 0000-0002-7827-3696
Sara PepeHematology, Department of Translational and Precision Medicine, Sapienza University, 00161 Rome, Italy.
Filomena De FalcoInstitute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06129 Perugia, Italy.ORCID 0000-0003-4008-2752
Veronica MattielloHematology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Luca BarabinoDepartment of Medical Sciences and Public Health, University of Cagliari, 09124 Cagliari, Italy.ORCID 0000-0002-3676-3240
Roberta AmiciNational Center for Global Health, Istituto Superiore di Sanità, 00161 Rome, Italy.
Marta CosciaDepartment of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10125 Torino, Italy.ORCID 0000-0003-2123-7675
Alessandra TedeschiASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
Corrado GirmeniaAzienda Policlinico Umberto I, 00161 Roma, Italy.
Livio TrentinHematology and Clinical Immunology Unit, Department of Medicine, University of Padua, 35122 Padova, Italy.ORCID 0000-0003-1222-6149
Silvia BaroncelliNational Center for Global Health, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-2050-9037
Sapienza University of Rome · ITIstituto Superiore di Sanità · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITUniversity of Padua · ITUniversity of Perugia · ITUniversity of Turin · ITAgostino Gemelli University Polyclinic · ITAzienda Ospedaliera G. Brotzu · ITAzienda Ospedaliera Pugliese Ciaccio · ITPoliclinico Umberto I · ITUniversità Campus Bio-Medico · ITUniversity of Cagliari · ITUniversity of Calabria · IT

Funding

AbbVie (United States) Not applicable
6 · The paper itself

Abstract

High morbidity and mortality due to COVID-19 were described in the pre-vaccination era in patients with chronic lymphocytic leukemia (CLL). To evaluate COVID-19 morbidity after the SARS-CoV-2 vaccine, we carried out a prospective study in 200 CLL patients. The median age of patients was 70 years; 35% showed IgG levels ≤ 550 mg/dL, 61% unmutated IGHV, and 34% showed

Indexed as

chronic lymphocytic leukemiaCOVID-19Omicron

Identifiers

PMID37296954
PMCPMC10251854
OpenAlexW4378882790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.